<DOC>
	<DOC>NCT01023685</DOC>
	<brief_summary>This study will investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients.</brief_summary>
	<brief_title>To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Patients who have completed the core study with no significant safety concerns Diagnosis of other neurodegenerative disease and/or psychiatric disorders (with the exception of successfully treated depression). Diagnosis or presence of an active, uncontrolled seizure disorder and/or cerebrovascular disease. Diagnosis or presence of an active autoimmune and/or with an acute or chronic inflammation. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Active immunization</keyword>
	<keyword>Alzheimer disease</keyword>
	<keyword>Antibody</keyword>
	<keyword>Central Nervous System diseases</keyword>
	<keyword>Neurodegenerative diseases</keyword>
	<keyword>Vaccine</keyword>
</DOC>